MedPath

Clinical Implications of Triple Combination Therapies(Metformin+Alpha-glucosidase Inhibitor+DPP-4 Inhibitor) in Type 2 Diabetes

Not Applicable
Conditions
Type 2 Diabetes mellitus
Registration Number
JPRN-UMIN000010061
Lead Sponsor
SANWA KAGAKU KENKYUSHO CO.,LTD
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
45
Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients require insulin or oral antidiabetic drug therapy other than metformin and/or miglitol 2.Female patients who were pregnant,suspected of being pregnant,planning a pregnancy,or lactating 3.Patients with,or a history of,serious renal disease(Serum Creatinine of >=2mg/dL 4.Any patients deemed by the investigator to be ineligible for participation in this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath